Investors, Inovio Get Final OK For $44M Deal In Stock Suit
A Pennsylvania federal judge on Wednesday approved a $44 million deal between biotechnology firm Inovio Pharmaceuticals Inc. and its investors to resolve claims that the company's alleged misrepresentation of its COVID-19...To view the full article, register now.
Already a subscriber? Click here to view full article